The rise in the Zydus Lifesciences shares came after the company received final approval from the United States Food and Drug ...

Zydus Lifesciences received final USFDA approval to manufacture Apalutamide tablets for prostate cancer, following last ...

Zydus Lifesciences shares rose 8.34 per cent on March 19, touching an intraday high of Rs 910.30  at 1:00 PM when the company ...

The company got the nod to manufacture and market apalutamide tablets, 60 mg, the generic equivalent of Erleada tablets, 60 ...

As per the IQVIA MAT January 2025 data, apalutamide tablets registered annual sales of $1099.80 million in the United States markets.

Brokerages deemed Zydus Life's acquisition of Amplitude Surgical as expensive, with subpar synergies that has triggered ...

Zydus Lifesciences rose 3% to an intra-day high of Rs 930 after the company received approval from the US FDA to manufacture ...

Nuvama is of the view that the Zydus Life's latest deal would be dilutive to the company's Earnings Per Share (EPS) by 1% to ...

Stocks including Bajaj Auto, LIC of India, Zydus Lifesciences, Dr Reddy's Labs, GR Infra, L&T, Granules India, Bharat ...

Zydus Lifesciences is working to advance its position in the global pharmaceutical sector by increasing its focus on medical ...

India's Zydus Lifesciences said on Tuesday it will acquire an 85.6% stake in France's Amplitude Surgical for 256.8 million ...

Zydus Lifesciences Ltd has received USFDA approval to manufacture a generic version of Apalutamide tablets for prostate cancer treatment. The 60 mg tablets will be produced in Ahmedabad, addressing a ...